EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Illuminating the FGFR fusion landscape in Chinese patients: unveiling novel molecular insights and clinical implications

Zhuo Liu, Dandan Zhao, Baoming Wang, Zhenyuan Qian, Zhengchuang Liu, Qiong Yang, Jinhua Tao, Yanxi Shao, Min Lv, Yanxiang Zhang, Jianhua Zhu, Jie Zhang und 5 weitere

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf347 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, 2025. Verfasst von Zhuo Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. Hauptthemen laut MEDLINE: Neoplasms, Oncogene Proteins, Fusion. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Chinese Medical Science and Technology Foundation, Zhejiang Medical and Health Technology Project, Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the increasing approval and ongoing clinical trials of FGFR-targeted therapies, accurately detecting FGFR fusions remains a challenge due to limited research, low incidence rates, complex fusion partner distribution, and unique kinase domain distribution.

Methods

We conducted a multicenter study to comprehensively profile FGFR fusions in the largest Chinese pan-cancer cohort to date, comprising 118 FGFR fusions from 114 individuals. Both DNA- and RNA-based sequencing approaches were utilized to reveal novel and fundamental features of FGFR fusion.

Results

Our research reveals an incidence rate of 0.96% for FGFR rearrangements within this Chinese cohort, including a high incidence rate of FGFR fusions (40%) in parotid gland carcinoma. However, this is based on a small sample size of 5 tumors and should be interpreted cautiously pending validation in larger cohorts. We also uncovered distinct breakpoint distribution patterns across various FGFR rearrangements. For example, a primary breakpoint in intron17 of FGFR2 was predominant (21/22), while FGFR1/3 breakpoints displayed substantial diversity. For the first time, we identified “hot” breakpoints in FGFR1 intron17, exon18, and FGFR3's 3’ untranslated region. These findings underline the importance of incorporating these regions in targeted sequencing to ensure comprehensive detection of FGFR1/3 fusions. Notably, we observed a predilection for intrachromosomal distribution in common FGFR1/2/3 fusions. In contrast, most novel fusions (12/15) exhibited an interchromosomal distribution pattern, indicating variations in the fusion formation mechanism. Importantly, our study demonstrates the substantial incremental value of RNA-NGS or other orthogonal methods in confirming the functionality of FGFR rearrangements initially identified by DNA sequencing. In our cohort, 46% (6/13) of rare FGFR1/2/3 fusions lacked detectable RNA transcripts; however, this does not definitively indicate non-functionality as factors such as low RNA quality, expression below detection limits, or nonsense-mediated decay may contribute. Therefore, RNA-based validation is critical for accurately identifying potentially targetable FGFR fusions and guiding therapy.

Conclusion

Our findings offer critical novel insights into functional FGFR fusions and bear considerable clinical implications for identifying individuals whose tumors are most likely to respond favorably to FGFR-targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsOncogene Proteins, FusionAdultAgedFemaleHumansMaleMiddle AgedChinaReceptor, Fibroblast Growth Factor, Type 1Receptor, Fibroblast Growth Factor, Type 2Receptor, Fibroblast Growth Factor, Type 3East Asian People

Stichwörter der Autor:innen

Chinese populationFGFRNGSmolecular profilingrearrangements

Substanzen

FGFR1 protein, humanFGFR3 protein, humanOncogene Proteins, FusionReceptor, Fibroblast Growth Factor, Type 1Receptor, Fibroblast Growth Factor, Type 2Receptor, Fibroblast Growth Factor, Type 3

Autor:innen und Institutionen

  • Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
  • College of Life Sciences, Jilin Agriculture University, Changchun 130118, China.
  • Jichenjunchuang Clinical Laboratory, Hangzhou 310000, China.
  • General Surgery, Cancer Center, Department of Gastrointestinal and Pancreatic Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou 310014, China.
  • Cancer Center, Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014…
  • Cancer Center, Clinical Research Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou 310014, China.

ORCID-Profile: Tonghui Ma

Förderung

  • Zhejiang Chinese Medical Science and Technology Foundation
  • Zhejiang Medical and Health Technology Project
  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Liu, Z., Zhao, D., Wang, B., Qian, Z., Liu, Z., Yang, Q., Tao, J., Shao, Y., Lv, M., Zhang, Y., Zhu, J., Zhang, J., Li, W., Wang, X., Wang, C., Ma, T., & Zhu, Y. (2025). Illuminating the FGFR fusion landscape in Chinese patients: unveiling novel molecular insights and clinical implications. The Oncologist. https://doi.org/10.1093/oncolo/oyaf347

Vancouver

Liu Z, Zhao D, Wang B, Qian Z, Liu Z, Yang Q, et al. Illuminating the FGFR fusion landscape in Chinese patients: unveiling novel molecular insights and clinical implications. The Oncologist. 2025. doi:10.1093/oncolo/oyaf347

BibTeX
@article{Liu2025,
  author = {Liu, Zhuo and Zhao, Dandan and Wang, Baoming and Qian, Zhenyuan and Liu, Zhengchuang and Yang, Qiong and Tao, Jinhua and Shao, Yanxi and Lv, Min and Zhang, Yanxiang and Zhu, Jianhua and Zhang, Jie and Li, Wei and Wang, Xiaojuan and Wang, Chunyang and Ma, Tonghui and Zhu, Yuping},
  title = {Illuminating the FGFR fusion landscape in Chinese patients: unveiling novel molecular insights and clinical implications},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf347}
}
Kostenlos starten →